20
KIT
We need research
to understand
whether the
benefits seen in
those with Type 1
diabetes can also
be demonstrated
in those with
Type 2 diabetes ~
Dr Emma Wilmot
Participants
might end up
being part of an
important change
in the way that
Type 2 diabetes
is monitored and
treated going
into the future ~
Dr Leelarathna
FreeDM2 - call to action!
Clinicians across the UK are asking for people to
participate in a study to assess the impact of the
FreeStyle Libre 3 continuous glucose monitoring on
outcomes in adults with Type 2 diabetes on basal insulin.
The purpose of the FreeDM2
study is to determine
whether continuous glucose
monitoring using FreeStyle
Libre 3 ((FSL3) will improve HbA1c-
among other measurements-
compared to using fingerprick blood
tests. People in the study will be
followed up for eight months.
The study is sponsored by
Abbott Diabetes Care. Its joint
chief investigators are leading
diabetologists Dr Emma Wilmot,
University of Nottingham and
Dr Lala Leelarathna, Imperial
College, London.
You are eligible if you are an adult
with sub-optimally controlled Type
2 diabetes on basal insulin therapy,
with an HbA1c between 7.5-11%.
Assessing any changes in HbA1c
is the main point of the study, which
is split into two phases each of four
months duration. The first phase is
participant-driven, while phase 2 is
HCP/therapy-driven. Participants
will be randomly allocated to either
FreeStyle Libre 3 (FSL3) or to
continue using their current blood
testing device. However, at the end of
the study, any of the participants who
end up in the latter group will also be
given a four-month supply of FSL3
with medical supervision as a way of
saying thank you for taking part.
www.freedm2.co.uk
Dr Lala Leelarathna
Dr Emma Wilmot